Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1128943

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Cancer Drugs Fund in meeting the needs of people with rarer and less common cancers.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	259175
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>Following the reforms to the Cancer Drugs Fund (CDF) in July 2016 all new cancer drugs and significant new licensed indications for existing drugs are referred to the National Institute for Health and Care Excellence (NICE). This included the referral of all licensed cancer drug indications for rare cancers that had not previously been assessed by NICE.</p><p>This has led to an increase in the number, and proportion, of NICE appraisals of treatments for rare cancers. Since July 2016 21% or 24 out of 114 cancer drugs appraised by NICE have been for rarer cancers, compared to 9% or 18 out of 200, before the CDF reforms. Of these 24 drugs for rare cancers, 22 have been recommended for routine commissioning and two for use within the CDF. This shows that changes to the appraisal and funding of cancer drugs has led to an increase in the number of treatments for rare cancers both assessed by NICE and funded by NHS England in routine commissioning and via the CDF.</p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:52:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3960 label Biography information for Henry Smith

1128945

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many clinical nurse specialists there were per patient with blood cancer in (a) 2015, (b) 2016 and (c) 2017.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	259177
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>NHS Digital publishes hospital and community health services workforce statistics for NHS trusts and clinical commissioning groups in England. However, NHS Digital does not separately identify specialist nurses such as clinical nurse specialists or those with a specialism of blood cancer.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 259176 question first answered 11/06/2019 16:43:14 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3960 label Biography information for Henry Smith

1128946

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will commit to providing a clinical nurse specialist for every patient with blood cancer by the end of 2019.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	259178
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>NHS England is committed to delivering the Long Term Plan which includes the requirement for all patients, including those with secondary cancers, to have access to the right expertise and support, including a clinical nurse specialist or other support worker.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:56:20 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3960 label Biography information for Henry Smith